Log In
Print
BCIQ
Print
Print this Print this
 

Incresync, Oseni, alogliptin/pioglitazone

Also known as: Liovel (alogliptin/Actos)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionOral combination of Nesina alogliptin plus Actos pioglitazone
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetes patients who are uncontrolled on existing therapies
Regulatory Designation

Partner

Furiex Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today